10-Q: Cadrenal Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cadrenal Therapeutics reported a net loss of $2.4 million for the third quarter of 2024, with increased operating expenses and ongoing development of their lead drug candidate, tecarfarin.

Summary

• Cadrenal Therapeutics reported a net loss of $2.4 million for the three months ended September 30, 2024, compared to a net loss of $1.0 million for the same period in 2023.
• The company's operating expenses increased to $2.5 million in the third quarter of 2024, up from $1.1 million in the third quarter of 2023, driven by higher general and administrative and research and development costs.
• For the nine months ended September 30, 2024, the net loss was $6.5 million, compared to a net loss of $7.2 million for the same period in 2023.
• The company's cash and cash equivalents were $4.4 million as of September 30, 2024, down from $8.4 million at the end of 2023.
• Cadrenal sold 154,144 shares of common stock through its at-the-market (ATM) facility during the quarter, generating net proceeds of $1.5 million.
• Subsequent to the quarter end, the company raised an additional $3.4 million through its ATM facility and $4.7 million through a warrant inducement transaction.
• The company expects its cash balance of $11.3 million as of November 7, 2024, to be sufficient to fund operations for at least the next twelve months, but additional funding will be needed for the Phase 3 clinical trial and New Drug Application.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in raising capital and has a cash runway for the next 12 months, the increased losses and operating expenses, along with the need for additional funding, create a negative sentiment. The potential of tecarfarin is a positive, but it is still in development.

Positives

• The company successfully raised $1.5 million through its ATM facility during the quarter.
• Subsequent to the quarter end, the company raised an additional $3.4 million through its ATM facility and $4.7 million through a warrant inducement transaction.
• The company's cash balance of $11.3 million as of November 7, 2024, is expected to be sufficient to fund operations for at least the next twelve months.

Negatives

• The company experienced a net loss of $2.4 million in the third quarter of 2024.
• Operating expenses increased significantly to $2.5 million in Q3 2024.
• Cash and cash equivalents decreased to $4.4 million as of September 30, 2024.
• The company will require additional funding to complete its planned Phase 3 clinical trial and submit its New Drug Application.

Risks

• The company has incurred significant losses and negative cash flows from operations since inception.
• Cadrenal will require additional funding to complete its planned Phase 3 clinical trial and submit its New Drug Application.
• There is no assurance that additional funding will be available on acceptable terms or at all.
• The company's liquidity may be negatively impacted by research and development cost increases and general economic and industry factors.
• The company's securities are listed on the Nasdaq Capital Market, and there is no assurance that the company will continue to comply with the listing requirements.

Future Outlook

The company expects its cash balance of approximately $11.3 million as of November 7, 2024, to be sufficient to fund its operations for at least the next twelve months, but additional funding will be required to complete the planned Phase 3 clinical trial and submit its New Drug Application.

Management Comments

• Management believes that tecarfarin is the only new anticoagulant being developed for patients with implanted cardiac devices and certain other rare cardiovascular conditions.
• Management anticipates that tecarfarin will address many of the bleeding and other adverse events and drug-to-drug interaction challenges of warfarin.
• Management aims to show that tecarfarin will provide less dosing variability, enhancing the quality of care for patients and reducing the time-consuming and costly hassles of dosing adjustments for healthcare providers.

Industry Context

The report highlights the need for new anticoagulants, particularly for patients with implanted cardiac devices, as current options like warfarin have limitations. The company's focus on tecarfarin, which uses a different metabolic pathway, addresses the challenges of drug interactions and kidney impairment common with existing treatments. This is relevant given the ongoing issues with warfarin and the lack of effective alternatives for specific patient populations.

Comparison to Industry Standards

• The document references the ARIES-HM3 study, which showed that the average time in therapeutic range (TTR) for warfarin was only 56%, far below the target of 70%. This highlights the challenges with current standard of care anticoagulation.
• The document mentions that recent randomized controlled trials in LVAD patients have documented that currently available VKAs yield poor quality anticoagulation despite the tight management of anticoagulation in the clinical trial setting. This suggests that Cadrenal's tecarfarin, with its potential for enhanced stability and TTR, could be a significant improvement over existing options.
• The document notes that there are approximately 15,000 patients in the U.S. with LVADs, and that these patients require chronic anticoagulation. This highlights the potential market for tecarfarin if it can demonstrate improved outcomes compared to warfarin.

Stakeholder Impact

• Shareholders are impacted by the increased losses and the need for additional capital, which may lead to dilution.
• Employees are impacted by the company's financial performance and the need to achieve milestones for the development of tecarfarin.
• Patients with implanted cardiac devices or rare cardiovascular conditions are impacted by the potential for a new, safer, and more effective anticoagulant.

Next Steps

• The company plans to initiate enrollment of patients and complete the planned pivotal Phase 3 trial for tecarfarin.
• The company will need to submit a New Drug Application (NDA) to the FDA.
• The company will continue to pursue clinical and commercial partnerships to advance tecarfarin.

Key Dates

Keywords

Tecarfarin, Anticoagulant, Clinical Trial, Phase 3, LVAD, ESKD, Atrial Fibrillation, Thrombosis, FDA, Orphan Drug Designation, Biopharmaceutical, Reverse Stock Split, ATM Facility, Warrant Inducement